Key Insights• According to the research report, "Australia EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Australia EPA & DHA Market is anticipated to grow at more than 38.15% CAGR from 2026 to 2031.The Australian EPA & DHA market is steadily expanding as the country faces population aging, a persistent burden of cardiovascular disease, rising concern about dementia, and one of the world's most established complementary medicines cultures, with fish oil long ranking among the most widely used supplements. According to the Australian Bureau of Statistics (ABS), Australia's population reached 27.9 million on March 31, 2026, growing 1.4% over the year, driven largely by net overseas migration. ABS cause-of-death statistics released in November 2025 show that in 2024 dementia, including Alzheimer's disease, became Australia's leading cause of death for the first time, accounting for 9.4% of deaths and more than 17,500 lives, overtaking ischaemic heart disease, which accounted for 8.7% of deaths. Coronary heart disease remains the leading cause of death among men, with 10,153 male deaths in 2024. Australia recorded 292,318 registered births in 2024, up from 286,998 in 2023, although the total fertility rate fell to a record low of 1.481. The combined burden of cardiovascular disease and cognitive decline is placing additional pressure on Australia's healthcare system and consumer health sector to strengthen access to EPA and DHA through complementary medicines, fortified foods, infant nutrition, and pet nutrition.• Australia's EPA & DHA market is characterized by a mature and export-oriented ecosystem comprising complementary medicine brands, pharmacy chains, omega-3 ingredient innovators, infant formula producers, and a large pet care sector.

Leading brands include Blackmores, Swisse (H&H Group), Nature's Way, Bioglan, and Ethical Nutrients, with distribution dominated by pharmacy chains such as Chemist Warehouse, whose merger with Sigma Healthcare was completed in February 2025, as well as Priceline, TerryWhite Chemmart, and supermarkets. Australian brands are also major exporters to China, where Australian and American brands lead foreign health supplement spending. Australia is home to Clover Corporation, which refines crude tuna oil in Melbourne into food-grade DHA and ARA powders for infant formula and reported FY25 revenue of AUD 48.4 million, up 38%. Nuseed, the seed technologies business of Nufarm, has developed omega-3 canola as a land-based source of EPA and DHA; following a strategic review launched in May 2025, Nufarm decided in November 2025 to retain the business while reducing the cash requirements of its omega-3 platform, after falling fish oil prices weighed on FY25 earnings.• Regulatory oversight for EPA and DHA products in Australia is administered by the Therapeutic Goods Administration (TGA) for complementary medicines and Food Standards Australia New Zealand (FSANZ) for foods. Fish oil, krill oil, and algal oil supplements are typically regulated as listed complementary medicines included in the Australian Register of Therapeutic Goods (ARTG) with an AUST L number, using permitted ingredients and permitted indications, and must be manufactured under Good Manufacturing Practice. Omega-3-fortified foods are regulated under the Australia New Zealand Food Standards Code, including Standard 1.2.7 on nutrition, health, and related claims.

In June 2024, FSANZ approved Proposal P1028, a major revision of the infant formula standard, which was gazetted in September 2024 with a five-year transition period, restructuring compositional, labelling, and specialized formula requirements in Australia. Prescription omega-3 medicines are registered on the ARTG and may be subsidized through the Pharmaceutical Benefits Scheme (PBS).Market Outlook• A defining characteristic of Australia's EPA & DHA market is the strong positioning of omega-3 within pharmacy-led complementary medicine and its close link to export demand. Australian consumers favor high-strength fish oils, odorless and small-capsule formats, krill oil, and combination products for heart, brain, eye, and joint health, while brands increasingly emphasize sustainability certifications such as MSC and Friend of the Sea. The country's strong reputation for quality and regulatory rigor supports exports of Australian omega-3 products to China and Southeast Asia through cross-border e-commerce and distribution partners. Simultaneously, the rise of dementia as the leading cause of death is reshaping consumer interest toward DHA-rich products positioned for cognitive health and healthy aging, while ingredient innovators such as Clover Corporation are expanding encapsulated DHA supply for infant formula and nutrition products in Europe and Asia.• The market also reflects Australia's growing emphasis on preventive health and healthy aging. The National Preventive Health Strategy and national dementia initiatives promote risk reduction through diet, physical activity, and cardiovascular health, providing a supportive backdrop for omega-3 positioned around heart and brain health.

In infant nutrition, the revised infant formula standard under P1028 is prompting manufacturers to reformulate and relabel products over the five-year transition period, while births of 292,318 in 2024 provide a stable domestic base. Australian infant formula producers such as a2 Milk and Bubs also export DHA-fortified formula to China and other Asian markets. The pet sector is a significant demand pocket, with 73% of Australian households owning a pet and annual pet spending of approximately AUD 21.3 billion, according to Animal Medicines Australia's September 2025 report.Market DynamicsDriver: Population aging, cardiovascular disease, and rising dementia burden supported by a strong complementary medicines cultureAustralia's EPA & DHA market is primarily driven by population aging and the combined burden of cardiovascular disease and dementia. Dementia became Australia's leading cause of death in 2024, accounting for 9.4% of deaths, while ischaemic heart disease accounted for 8.7% of deaths and remained the leading cause of death among men, according to the ABS. Australians are among the world's most frequent users of complementary medicines, with fish oil long established as a pharmacy staple. TGA-permitted indications allow listed omega-3 medicines to communicate benefits for heart health, brain function, eye health, and joint health.

As awareness of cardiovascular prevention and cognitive health continues to grow, pharmacies and supermarkets are witnessing sustained demand for EPA and DHA products, with DHA-rich formats gaining attention for brain health.Challenge: Retail consolidation, raw material volatility, and complementary medicine regulatory scrutinyOne of the principal challenges facing Australia's EPA & DHA market is the concentration of retail power following the merger of Chemist Warehouse and Sigma Healthcare in February 2025, which strengthens retailer bargaining power and intensifies price promotion in the omega-3 category. At the same time, raw material costs remain volatile. Peru's first 2026 north-central anchovy quota was set approximately 36% lower than in 2025, while the Antarctic krill fishery closed early on August 1, 2025, and again on August 12, 2026. Falling fish oil prices in 2025 also affected the economics of alternative omega-3 sources, with Nufarm attributing losses in its emerging crops platform largely to lower fish oil prices. Additionally, the TGA continues to scrutinize the evidence underpinning permitted indications and advertising claims for complementary medicines, requiring brands to maintain robust substantiation. Together, these factors contribute to margin pressure and the need for continued investment in quality and evidence.Trend: Cognitive health positioning, land- and algae-based omega-3 innovation, and export growthAustralia is experiencing a significant shift toward cognitive health and healthy aging positioning for omega-3, alongside innovation in alternative omega-3 sources.

The emergence of dementia as the leading cause of death is encouraging brands to develop DHA-focused products and combination formulas targeting memory and brain health. Australian companies are also contributing to sustainable omega-3 innovation, with Nuseed's omega-3 canola offering a land-based source of long-chain omega-3 for aquaculture and human nutrition, and Clover Corporation's encapsulation technology enabling DHA fortification of infant formula and foods. Algal omega-3 is gaining share in vegan and prenatal ranges. Exports to China and Southeast Asia through cross-border e-commerce remain a key growth channel for Australian omega-3 brands. The growing pet sector, with an estimated 31.6 million pets including about 7.4 million dogs, is also boosting demand for fish oil-enriched pet foods and supplements.Policies• TGA Listed Complementary Medicines: Omega-3 supplements containing EPA and DHA are generally regulated as listed complementary medicines on the ARTG with an AUST L number, using ingredients and indications from the TGA's permitted lists. Sponsors must hold evidence supporting their indications, and products must be manufactured under TGA-recognized Good Manufacturing Practice.• Therapeutic Goods Advertising Code: Advertising of omega-3 complementary medicines must comply with the Therapeutic Goods Advertising Code, which requires claims to be accurate, balanced, and consistent with the product's ARTG entry, with the TGA enforcing compliance.• Food Standards Code and Health Claims: Omega-3-fortified foods are regulated under the Australia New Zealand Food Standards Code, with Standard 1.2.7 governing nutrition content claims and health claims, including permitted claims relating to omega-3 fatty acids and heart health, subject to qualifying conditions.• Infant Formula Standard (P1028): FSANZ approved Proposal P1028 in June 2024, revising Standard 2.9.1 on infant formula products.

Gazetted in September 2024 with a five-year transition period, the revised standard restructures compositional requirements, introduces a specialized category for infants with medical conditions, and updates labelling requirements in Australia.• Prescription Medicines and PBS: Prescription omega-3 medicines are registered on the ARTG and may be subsidized through the PBS based on recommendations from the Pharmaceutical Benefits Advisory Committee.Segment AnalysisAustralia EPA & DHA Market By Product Type• EPA–DHA Blends represent the largest revenue-generating product category in Australia due to their widespread use in high-strength fish oil, krill oil, and combination products sold through pharmacies and supermarkets. Blended products are positioned for heart, joint, and general wellness, with ischaemic heart disease accounting for 8.7% of deaths in 2024.• Docosahexaenoic Acid (DHA) maintains an important and growing position within Australia, particularly in infant formula, prenatal supplements, and cognitive health products, with the emergence of dementia as the leading cause of death boosting interest in DHA for brain health.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Australia, driven by interest in high-EPA concentrates for cardiovascular health, inflammation-related wellness, and mood support.Australia EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Australia due to its cost-effectiveness and long-standing consumer familiarity, with Clover Corporation also refining tuna oil domestically for DHA ingredient production.• Algae Oil maintains a growing position within Australia, particularly in vegan, prenatal, and infant formula products, supported by demand for sustainable and contaminant-free omega-3.• Krill Oil is a significant premium source category in Australia, positioned for absorption and smaller capsule size and supported by strong pharmacy distribution.• Other Marine Sources hold a niche position in the Australian market, including green-lipped mussel, salmon oil, and calamari oil, as well as land-based omega-3 canola oil, primarily used in joint health products, specialty supplements, and aquaculture feed.Australia EPA & DHA Market By Application• Dietary Supplements, primarily listed complementary medicines, represent the largest application segment in Australia, distributed through pharmacy chains, supermarkets, and e-commerce, with significant export sales to China.• Infant Formula represents a strategically important application segment, with DHA widely included in formulas produced for domestic and export markets, and manufacturers adapting to the revised P1028 standard.• Pharmaceuticals represent a smaller application segment, including prescription omega-3 medicines for hypertriglyceridemia registered on the ARTG.• Food & Beverages encompasses omega-3-enriched milk, bread, eggs, and spreads, regulated under the Food Standards Code.• Clinical Nutrition & Medical Foods includes enteral and parenteral nutrition products containing fish oil, used in hospitals and aged care facilities.• Pet Nutrition represents the fastest-growing application segment in Australia, supported by 73% household pet ownership, an estimated 31.6 million pets, and annual pet spending of approximately AUD 21.3 billion, according to Animal Medicines Australia.Major EPA & DHA Manufacturers Operating in Australia• Blackmores, H&H Group (Swisse), Nature's Way, Bioglan, Ethical Nutrients, Clover Corporation, Nuseed (Nufarm), a2 Milk, Bubs Australia, Nestlé, Danone, dsm-firmenich, and Aker BioMarine are leading players in the Australian EPA & DHA market, offering fish oil and krill oil supplements, DHA ingredients, omega-3 canola, and DHA-fortified infant formula. Clover Corporation reported FY25 revenue of AUD 48.4 million, up 38%, while Nufarm retained its seed technologies business, including omega-3 canola, following a 2025 strategic review. Their strong presence, pharmacy partnerships, export capabilities, and scientific support programs have driven adoption across the Australian market.• The market is also supported by contract manufacturers, softgel producers, ingredient distributors, and testing laboratories that provide formulation, encapsulation, and quality assurance support. With strong export links to Asia and innovation in alternative omega-3 sources, Australia remains an important omega-3 market in the Asia-Pacific region.Australia EPA & DHA Supply and Pricing Economics• EPA and DHA products in Australia represent value-added nutritional products whose pricing depends on source, concentration, certification, and channel. Pricing varies considerably between supermarket fish oil, pharmacy brands, krill oil, and algal oil.• Imported refined oil prices are influenced by the Australian dollar and global raw material costs.

Fish oil prices declined in 2025, affecting the competitiveness of alternative omega-3 sources, while the reduced 2026 Peruvian quota is expected to place renewed upward pressure on prices.• Complementary medicines are paid out-of-pocket, with frequent half-price promotions in pharmacy chains shaping consumer purchasing. Prescription omega-3 medicines may be subsidized through the PBS for eligible patients.• Export pricing to China is influenced by cross-border e-commerce dynamics and competition from other foreign and domestic Chinese brands.Market Outlook by Consumer Health Spending and Supply Infrastructure• Australia's EPA & DHA market growth is strongly linked to population aging, consumer health spending, and the strength of pharmacy and export channels, although retail consolidation and raw material volatility remain significant factors influencing profitability.• Private consumer spending drives the supplement and pet nutrition segments, while exports to China and Southeast Asia provide an important additional growth channel for Australian brands.• The future growth opportunity for EPA and DHA in Australia depends on capturing demand for cognitive health and healthy aging, sustaining export growth, adapting infant formula to the revised P1028 standard, and advancing land- and algae-based omega-3 innovation. Greater integration of omega-3 within preventive health and dementia risk reduction strategies will likely become key strategies for long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.